Sökning: onr:"swepub:oai:DiVA.org:uu-127383" >
Multicentre phase I...
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
-
Reardon, A (författare)
-
Dresemann, G (författare)
-
Taillibert, S (författare)
-
visa fler...
-
Campone, M (författare)
-
van den Bent, M (författare)
-
Clement, P (författare)
-
- Blomquist, E (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi
-
Gordower, L (författare)
-
Schultz, H (författare)
-
Raizer, J (författare)
-
Hau, P (författare)
-
Easaw, J (författare)
-
Gil, M (författare)
-
Tonn, J (författare)
-
Gijtenbeek, A (författare)
-
Schlegel, U (författare)
-
Bergstrom, P (författare)
-
Green, S (författare)
-
Weir, A (författare)
-
Nikolova, Z (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009-11-10
- 2009
- Engelska.
-
Ingår i: British Journal of Cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 101:12, s. 1995-2004
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). RESULTS: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). CONCLUSION: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity. British Journal of Cancer (2009) 101, 1995-2004. doi: 10.1038/sj.bjc.6605411 www.bjcancer.com Published online 10 November 2009 (C) 2009 Cancer Research UK
Nyckelord
- glioblastoma
- imatinib mesylate
- platelet-derived growth factor
- c-KIT
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Reardon, A
-
Dresemann, G
-
Taillibert, S
-
Campone, M
-
van den Bent, M
-
Clement, P
-
visa fler...
-
Blomquist, E
-
Gordower, L
-
Schultz, H
-
Raizer, J
-
Hau, P
-
Easaw, J
-
Gil, M
-
Tonn, J
-
Gijtenbeek, A
-
Schlegel, U
-
Bergstrom, P
-
Green, S
-
Weir, A
-
Nikolova, Z
-
visa färre...
- Artiklar i publikationen
-
British Journal ...
- Av lärosätet
-
Uppsala universitet